Cavion
Latest round
- Series A
Last raised
- Jan 2017
Total raised
- $26M
Investors
- 3
About Cavion
Cavion, Inc.Founded in 2014 in Charlottesville, US, Cavion, Inc. specializes in creating therapies for neurological and cancer-related conditions. The company was acquired by Jazz Pharmaceuticals, Inc.5 mn, with a potential additional payment of USD 260 mn based on performance milestones.Cavion Pharma specializes in developing innovative therapeutic solutions aimed at addressing unmet medical needs in neurology and oncology. The company’s core product offerings include proprietary drug candidates that target specific pathways involved in neuronal and cancer cell dysfunction. These therapeutics are designed to improve patient outcomes through mechanisms that modulate cellular signaling and promote neuroprotection or inhibit tumor growth. Cavion Pharma primarily serves a diverse client base, including hospitals, specialty pharmacies, and healthcare providers, facilitating access to their treatment options for patients dealing with chronic neurological conditions and various cancer types.Cavion Pharma engages in a business model characterized by partnerships with healthcare institutions and pharmaceutical distributors to maximize the reach of its products. Revenue generation occurs through direct sales of their flagship drug candidates to healthcare providers and institutions, as well as through potential licensing agreements with larger pharmaceutical companies seeking to leverage Cavion's proprietary technologies. Transactions typically involve negotiated pricing structures tailored to the needs of hospitals and clinics, reflecting the value of the therapies in improving patient care.Cavion's strategy includes the development of new drug candidates aimed at enhancing treatment options in neurology and oncology, with several projects in the pipeline for the upcoming years. The company plans to expand its market presence into additional European countries and parts of Asia by 2025, targeting regions that require advanced therapeutic solutions. The recent acquisition by Jazz Pharmaceuticals, Inc. will support these initiatives, providing necessary resources and expertise to accelerate product development and market expansion.
Who invested in Cavion
3 investors across 1 round
See all investors in Cavion
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 6, 2017
Amount
$26M
Investors
Questions about Cavion
Who invested in Cavion?
Cavion has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cavion raised?
Cavion has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cavion last raise money?
Cavion's most recent round on record is a Series A, in Jan 2017.
What does Cavion do?
Cavion is a pharmaceuticals company.
Where is Cavion headquartered?
Cavion is headquartered in Charlottesville, US.
Which VCs invest in companies like Cavion?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cavion's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Cavion? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.